Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC

Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC

Conference

ESMO 2020

25 November, 2020 15:02

Systemic therapy of brain metastases

Presented By

Dr Natasha Leighl, Dr Edrune Arriola Aperribay

Trial

Phase 3, FLAURA, ALEX, ALTA-1L, AURA3

Conference

ELCC 2019

25 June, 2019 08:09

Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer

Presented By

Dr Ross Camidge, University of Colorado Cancer Center, USA

Trial

Phase 3, ALTA-1L

Conference

WCLC 2018

21 November, 2018 22:31

Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC

Conference

WCLC 2018

21 November, 2018 22:24

Entrectinib treatment in patients with ROS1+ NSCLC

Trial

STARTRK-2, STARTRK-1, ALKA-372-001

Conference

WClC 2018

21 November, 2018 21:57

Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative

Conference

WCLC 2018

21 November, 2018 21:28

ALK inhibition, guidelines, liquid biopsies, and immunotherapy

Presented By

Dr Céline Mascaux, Aix-Marseille University, France

Trial

AURA3, FLAURA

Conference

ERS 2018

7 November, 2018 22:31

Medical Conferences

Tag: crizotinib